Catalent to supply the newly approved Exelixis CometriqT (Cabozantinib) in the US market

“Catalent supports pharmaceutical companies, small and large, to help them accelerate their drug development and bring new treatments to improve patient’s lives.”   Said Scott Houlton, President, Development and Clinical Services of Catalent. “We have worked closely with Exelixis over the past several years on COMETRIQ and are delighted to have reached this key milestone.”

“We have been pleased to partner with Catalent over the last 5 years. Catalent has provided high quality service for analytical testing, manufacturing process development and validation.  This partnership has truly helped advance this important product for cancer patients,” said JoAnn Wilson, Vice President, Chemical, Manufacturing and Control at Exelixis, Inc.

All U.S. COMETRIQ capsule manufacturing and packaging operations will be undertaken at Catalent’s 450,000 sq ft, Kansas City, MO facility, which provides a range of fully integrated support services, from formulation development and analytical testing, to clinical supply services as well as clinical and commercial scale manufacturing and packaging of a variety oral dose forms.